[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rett Syndrome Research Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100431621","the-rett-syndrome-global-registry-100431621",false,"NCT04900493","The Rett Syndrome Global Registry","Inclusion Criteria:\n\n1. Parent\u002Fcaregiver must be willing and able to provide written informed consent electronically prior to entering data into the registry.\n2. Rett individuals of any age, living or deceased, must have a diagnosis of Rett syndrome and\u002For have a mutation in MECP2.\n\nExclusion Criteria:\n\n1. Individuals who have a genetic mutation that is inconsistent with Rett syndrome or who have a different disorder.\n2. Individuals with MECP2 Duplication Syndrome","ALL",{"count":17,"type":18},5000,"ESTIMATED","5 Years","OBSERVATIONAL","The Rett Global Registry is a fully remote, global, caregiver-reported registry to collect information about caring for a loved one with Rett syndrome. In addition, caregivers have the ability to track and graph their loved one's symptoms and care strategies over time, store information for central access, and opt-in to complete medical record consolidation and summary. Qualified researchers and therapeutic developers may request access to de-identified aggregate information to further Rett research, or assist with clinical development planning to facilitate and expedite more effective clinical trials.",[23],"Rett Syndrome",[25,26,27],"MECP2","Registry","RSRT","RECRUITING","2026-02-12",{"date":31,"type":32},"2026-02-17","ACTUAL",{"date":34,"type":32},"2022-01-31",{"date":36,"type":18},"2031-06-30",{"name":38,"class":39},"Rett Syndrome Research Trust","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100542084","validating-innovative-biosensors-for-rett-autonomic-symptom-tracking-100542084","NCT06338267","Validating Innovative Biosensors for Rett Autonomic Symptom Tracking","Validation of Innovative Biosensors for Rett Autonomic Symptom Tracking","VIBRANT","Inclusion Criteria:\n\n* diagnosis of Rett syndrome with a causative MECP2 genetic variant\n* Access to WiFi\n\nExclusion Criteria:\n\n* Inability of participant to sleep alone\n* prolonged absence from home\n* medication use that may impact heart rate",{"count":50,"type":18},30,"The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients with Rett syndrome for up to 9 weeks. Symptoms of interest include heart rate, breathing, sleep, blood oxygen levels, and movement. Participants will use the biosensors intermittently at home, document device use and symptom status, and will come to the clinic for 1 overnight sleep study. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year.\n\nThe study will provide information on the feasibility and ease of use for families at home, biosensor data will be compared to data collected at the same time from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome, and Emerald will be developed to include movement as a measurable symptom.",[23],[54,25,55,56,57,58,59,60,61],"Rett","RTT","device","biosensor","Emerald","Vivalink","Kids O2","sensor","2025-12-18",{"date":64,"type":32},"2025-12-19",{"date":66,"type":32},"2025-03-03",{"date":68,"type":18},"2026-06",{"name":38,"class":39},3,""]